US protection ending in 2029: Eye
As of the edition of 20 October 2026, 12 drugs have US protection that ends in 2029 in eye; 7 of them have at least one company on route B because of it.
Sources: FDA Orange Book and Purple Book, other approval registers.
12 drugs
| Drug | US protection | Status | Holder | Target | Route B rows |
|---|---|---|---|---|---|
| Amifampridine | Ends 2029 (exclusivity) | Marketed | Angelini Pharma | 0 | |
| Avelumab | Ends 2029 (computed from the first US licence) | Marketed | Merck KGaA | CD274 | 1 |
| Budesonide | Ends 2029 (exclusivity) | Marketed | NR3C1 | 5 | |
| Crisaborole | Ends 2029 (patent) | Marketed | Pfizer | PDE4A, PDE4B, PDE4C | 0 |
| Crizotinib | Ends 2029 (patent) | Marketed | Pfizer | ALK, MET, ROS1 | 2 |
| Dapagliflozin | Ends 2029 (patent) | Marketed | AstraZeneca | SLC5A2 | 2 |
| Edaravone | Ends 2029 (exclusivity) | Marketed | Shionogi | 0 | |
| Florbetaben | Ends 2029 (patent) | Marketed | Lantheus Biosciences | 0 | |
| Latanoprostene bunod | Ends 2029 (patent) | Marketed | Bausch Health | PTGFR | 1 |
| Ruxolitinib | Ends 2029 (exclusivity) | Marketed | JAK1, JAK2 | 4 | |
| Sarilumab | Ends 2029 (computed from the first US licence) | Marketed | Sanofi | IL6R | 1 |
| Voretigene neparvovec | Ends 2029 (computed from the first US licence) | Marketed | Roche | 0 |
Listed by name. A route B row is one company at one target; for a drug with one target that is the number of companies. US protection is the US only, and it is not the date generics or biosimilars can enter.
Which companies are on route B in 2029 in eye
In the product7 of these 12 drugs have at least one company on route B. Which companies, and their scores, are in the product.
Get this list with the companies, scores and sources as a fileRequest access. Nothing is shown until you do.